Novartis shares slip, Avidity soars after $12 billion biotech deal
NegativeFinancial Markets

Novartis shares have taken a hit following a significant $12 billion deal in the biotech sector, while Avidity's stock has surged as a result. This shift highlights the volatility in the biotech market and the impact of major transactions on company valuations. Investors are closely watching how these changes will affect future growth and innovation in the industry.
— Curated by the World Pulse Now AI Editorial System













